O
Oscar M. Rueda
Researcher at University of Cambridge
Publications - 116
Citations - 17234
Oscar M. Rueda is an academic researcher from University of Cambridge. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 38, co-authored 107 publications receiving 13941 citations. Previous affiliations of Oscar M. Rueda include Cancer Research UK & Utrecht University.
Papers
More filters
Journal ArticleDOI
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
Christina Curtis,Christina Curtis,Sohrab P. Shah,Suet-Feung Chin,Gulisa Turashvili,Oscar M. Rueda,Mark J Dunning,Doug Speed,Doug Speed,Andy G. Lynch,Shamith A. Samarajiwa,Yinyin Yuan,Stefan Gräf,Gavin Ha,Gholamreza Haffari,Ali Bashashati,Roslin Russell,Steven McKinney,Anita Langerød,Andrew R. Green,Elena Provenzano,Gordon C. Wishart,Sarah E Pinder,Peter H. Watson,Peter H. Watson,Florian Markowetz,Leigh C. Murphy,Ian O. Ellis,Arnie Purushotham,Arnie Purushotham,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,James D. Brenton,Simon Tavaré,Carlos Caldas,Samuel Aparicio +35 more
TL;DR: The results provide a novel molecular stratification of the breast cancer population, derived from the impact of somatic CNAs on the transcriptome, and identify novel subgroups with distinct clinical outcomes, which reproduced in the validation cohort.
Journal ArticleDOI
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson,Dana W.Y. Tsui,Muhammed Murtaza,Heather Biggs,Oscar M. Rueda,Suet-Feung Chin,Mark J Dunning,Davina Gale,Tim Forshew,Betania Mahler-Araujo,Sabrina Rajan,Sean Humphray,Jennifer Becq,David Halsall,Matthew G. Wallis,David Bentley,Carlos Caldas,Nitzan Rosenfeld +17 more
TL;DR: This proof-of-concept analysis showed that circulating tumor DNA is an informative, inherently specific, and highly sensitive biomarker of metastatic breast cancer.
Journal ArticleDOI
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Sohrab P. Shah,Andrew Roth,Rodrigo Goya,Arusha Oloumi,Gavin Ha,Yongjun Zhao,Gulisa Turashvili,Jiarui Ding,Kane Tse,Gholamreza Haffari,Ali Bashashati,Leah M Prentice,Jaswinder Khattra,Angela Burleigh,Damian Yap,Virginie Bernard,Andrew McPherson,Karey Shumansky,Anamaria Crisan,Ryan Giuliany,Alireza Heravi-Moussavi,Jamie Rosner,Daniel Lai,Inanc Birol,Richard Varhol,Angela Tam,Noreen Dhalla,Thomas Zeng,Kevin C. Ma,Simon K. Chan,Malachi Griffith,Annie Moradian,S.-W. Grace Cheng,Gregg B. Morin,Peter H. Watson,Karen A. Gelmon,Stephen Chia,Suet-Feung Chin,Christina Curtis,Christina Curtis,Oscar M. Rueda,Paul D.P. Pharoah,Sambasivarao Damaraju,John R. Mackey,Kelly Hoon,Timothy T. Harkins,Vasisht Tadigotla,Mahvash Sigaroudinia,Philippe Gascard,Thea D. Tlsty,Joseph F. Costello,Irmtraud M. Meyer,Connie J. Eaves,Wyeth W. Wasserman,Steven J.M. Jones,Steven J.M. Jones,David G. Huntsman,David G. Huntsman,Martin Hirst,Carlos Caldas,Marco A. Marra,Samuel Aparicio +61 more
TL;DR: It is shown that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes, and for the first time in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population is determined.
Journal ArticleDOI
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira,Suet-Feung Chin,Oscar M. Rueda,Hans Kristian Moen Vollan,Elena Provenzano,Helen Bardwell,Michelle Pugh,Linda Jones,Roslin Russell,Stephen John Sammut,Dana W.Y. Tsui,Bin Liu,Sarah-Jane Dawson,Sarah-Jane Dawson,Jean Abraham,Helen Northen,John F. Peden,Abhik Mukherjee,Gulisa Turashvili,Andrew R. Green,Steve McKinney,Arusha Oloumi,Sohrab P. Shah,Nitzan Rosenfeld,Leigh C. Murphy,David R. Bentley,Ian O. Ellis,Arnie Purushotham,Sarah E Pinder,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Helena M. Earl,Paul D.P. Pharoah,Mark T. Ross,Samuel Aparicio,Carlos Caldas +35 more
TL;DR: This study sequence 173 genes in 2,433 primary breast tumours that have copy number aberration, gene expression and long-term clinical follow-up data, and determines associations between mutations, driver CNA profiles, clinical-pathological parameters and survival.
Journal ArticleDOI
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Annette T. Byrne,D Alferez,Frédéric Amant,Daniela Annibali,Joaquín Arribas,Andrew V. Biankin,Andrew V. Biankin,Alejandra Bruna,Eva Budinská,Carlos Caldas,David K. Chang,Robert Clarke,Hans Clevers,George Coukos,Virginie Dangles-Marie,S. Gail Eckhardt,Eva González-Suárez,Els Hermans,Manuel Hidalgo,Monika A. Jarzabek,Steven de Jong,Jos Jonkers,Kristel Kemper,Luisa Lanfrancone,Gunhild Mari Mælandsmo,Elisabetta Marangoni,Jean-Christophe Marine,Enzo Medico,Jens Henrik Norum,Héctor G. Palmer,Daniel S. Peeper,Pier Giuseppe Pelicci,Alejandro Piris-Giménez,Sergio Roman-Roman,Oscar M. Rueda,Joan Seoane,Violeta Serra,Laura Soucek,Dominique Vanhecke,Alberto Villanueva,Emilie Vinolo,Andrea Bertotti,Livio Trusolino +42 more
TL;DR: Patient derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology as mentioned in this paper, and the ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions.